Previous 10 | Next 10 |
These Penny Stocks Are Expecting To Release New Data This Week If there’s one thing investing in penny stocks has taught us, it’s to look for potential catalysts anywhere you can find them. Sometimes it’s easier said than done, to be honest. But proper research is a skil...
Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP ) +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...
Acasti Pharma (NASDAQ: ACST ) -66% after unsuccessful results from a Phase 3 TRILOGY 1 trial. More news on: Acasti Pharma Inc., Stage Stores, Inc., Five Below, Inc., Stocks on the move, Read more ...
Investors in Aquestive Therapeutics (NASDAQ: AQST ) can breathe a bit easier on the potential FDA nod for Libervant (diazepam) Buccal Film for the potential treatment of intermittent stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that ar...
WARREN, N.J., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today reported that the U....
Aquestive Therapeutics (NASDAQ: AQST ) is up 13% premarket on light volume on the heels of its announcement of preliminary Q4 and 2019 revenues of ~$16M and ~$52M, respectively, both above consensus. More news on: Aquestive Therapeutics, Inc., Healthcare stocks news, Stocks o...
Anticipates full year 2019 preliminary unaudited total revenues to be approximately $52 million, exceeding previously provided full year revenue guidance Anticipates fourth quarter 2019 preliminary unaudited total revenues to be approximately $16 million Expects preliminary unaudited c...
Aquestive Therapeutics ( AQST ) continues to evolve into a promising long-term investment. The company has completed its Libervant rolling NDA and received FDA approval for Exservan in ALS. In addition, Aquestive reported more than 50% growth of Sympazan shipments to retailers in Q3. What is m...
The following slide deck was published by Aquestive Therapeutics, Inc. in conjunction with this Read more ...
Gainers: LMP Automotive (NASDAQ: LMPX ) +95% . More news on: LMP Automotive Holdings, Inc., Sarepta Therapeutics, Inc., Cohen & Company Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDA Expanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distri...
Clearwater Paper Corporation (CLW) is expected to report for Q2 2024 Amgen Inc. (AMGN) is expected to report $4.93 for Q2 2024 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.47 for Q2 2024 Axon Enterprise Inc. (AXON) is expected to report $0.55 for Q2 2024 Ame...
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...